LONGEVA.

Epitalon: limits of adverse-event evidence

Khavinson and colleagues’ 2003 study added epitalon to cultured human fetal fibroblasts and examined telomerase and telomeres. The inspected abstract describes a cell experiment and gives no patient adverse-event frequencies. [1]

This abstract cannot establish a clinical adverse-reaction profile or human safety for epitalon. A cell model also does not establish safety of a particular reagent batch. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Adverse events in patientsCultured human fetal fibroblasts (cell experiment)The abstract gives no patient adverse-event frequencies; a clinical adverse-reaction profile cannot be established from it[1]

References

  1. Khavinson VKh et al. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells https://doi.org/10.1023/A:1025493705728.